Traditional Chinese medicine composition for treating and / or preventing osteoporosis and application thereof
By optimizing the component ratio and extraction method of Ligustrum Chinese medicine composition, the problem of inconsistent treatment effect of Ligustrum decoction extract was solved, and more efficient treatment and prevention of osteoporosis was achieved, especially for postmenopausal bone mass Loose disease has significant therapeutic effects and ensures the safety of the drug.
Patent Information
- Application Number
- CN202411118669.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-12
AI Technical Summary
Prior Art In the treatment and prevention of postmenopausal osteoporosis, the difference in the proportion of effective ingredients and components of the primate decoction extract leads to inconsistent treatment effects, and the safety and efficiency are insufficient, making it difficult to effectively reverse bone metabolism disorders caused by iron overload. .
Optimize the component ratio of cycloalether terpenes, phenylethanol, triterpenes and polysaccharides in Ligustrum, and prepare a traditional Chinese medicine composition, including specific mass ratios, such as phenylethanol: cycloalether terpenes: triterpenes Category: Ligustrum polysaccharide = 1:1.0:0.9:63.8, the effective ingredient extraction rate is improved through gradient reflux extraction, forming a more efficient anti-osteoporosis drug.
It significantly improves the bone mineralization formation and repair effect of osteoporosis, especially for osteoporosis accompanied by iron overload, and is safe and has good long-term use.
Smart Images

Figure CN118924809A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating and / or preventing osteoporosis and application thereof. Background Art
[0002] Osteoporosis (OP) is a systemic bone metabolic disease that causes bone loss and bone microstructure destruction caused by multiple factors, which increases bone fragility and susceptibility to fracture. It can be divided into primary and secondary types. Postmenopausal osteoporosis (PMOP) is the most common primary osteoporosis. It is a systemic bone metabolic disease characterized by decreased bone mass, degeneration of bone tissue microstructure, bone fragility and increased susceptibility to fractures, due to the decline of ovarian function in postmenopausal women, decreased estrogen levels, and bone absorption greater than bone formation. The most common and serious phenomenon of PMOP is fragility fractures in multiple bone sites, especially the hip joint and vertebrae. Up to 50% of postmenopausal women worldwide suffer from PMOP, and its prevalence will further increase with the aging of the population. Therefore, PMOP has become a global problem affecting the health of middle-aged and elderly women.
[0003] Clinical studies have found that 5-10 years after the cessation of menstruation, the serum ferritin level of PMOP patients is 2-3 times that of premenopause. Serum ferritin concentration is the main indicator for judging the body's iron level. Therefore, PMOP is not simply a problem of bone metabolism disorder. Its iron overload phenomenon has been recognized as a risk factor by multiple centers at home and abroad. Animal model studies have shown that iron overload also induces severe bone loss. In vitro studies have also found that iron overload not only inhibits the proliferation and differentiation of osteoblasts, but also promotes bone resorption by promoting osteoclastogenesis and increasing osteoclast activity. It can be seen that iron overload is a clinical risk factor that exacerbates the occurrence and development of PMOP, and reversing the bone metabolism disorder caused by iron overload is an effective way to prevent and treat PMOP.
[0004] Ligustrum lucidum is the dried mature fruit of Ligustrum lucidum Ait., a plant of the Oleaceae family. It is sweet in taste and cool in nature. It belongs to the liver and kidney meridians. It has the effects of nourishing the liver and kidney, improving eyesight and blackening hair. It is mostly used to treat liver and kidney yin deficiency, dizziness and tinnitus, soreness of the waist and knees, and premature graying of hair. Ligustrum lucidum is included in the recommended medication of the 2020 edition of the "Guidelines for Clinical Practice of Postmenopausal Osteoporosis in Traditional Chinese Medicine". Modern studies have shown that Ligustrum lucidum contains rich pharmacological substances, mainly including phenylethanol compounds (salidroside, tyrosol), iridoid compounds (terligustrin, oleuropein), triterpenoid compounds (oleanolic acid, ursolic acid), Ligustrum lucidum polysaccharides, etc. Previous studies have found that Ligustrum lucidum decoction pieces extract can reverse iron overload and resist PMOP through the BMP / SMAD pathway. It was also found in the early stage that the different ratios of phenylethanol, iridoids, triterpenes and polysaccharides in Ligustrum lucidum decoction pieces would lead to differences in their anti-PMOP efficacy. Therefore, it is necessary to develop a more efficient, scientific, and quality-controlled Chinese medicine composition for preventing and treating osteoporosis. Summary of the invention
[0005] In view of some deficiencies in the prior art, the present invention provides a Chinese medicine composition for treating and / or preventing osteoporosis and its application; the present invention optimizes the combination of multiple active ingredients to obtain a Chinese medicine composition for treating and / or preventing osteoporosis; the Chinese medicine composition comprises iridoid compounds, phenethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide, and the Chinese medicine composition can effectively prevent and treat osteoporosis, especially postmenopausal osteoporosis; the Chinese medicine composition has a better effect on preventing and treating osteoporosis than Ligustrum lucidum slices (raw product, wine-steamed product) extract and positive drugs, has good safety for long-term use, and has good practicality.
[0006] In order to achieve the above technical objectives, the present invention adopts the following technical means:
[0007] The invention firstly provides a traditional Chinese medicine composition for treating and / or preventing osteoporosis. The traditional Chinese medicine composition comprises iridoid compounds, phenethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide.
[0008] Preferably, the iridoid compounds, phenethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide are extracted from Ligustrum lucidum.
[0009] Preferably, the iridoids include one or more of ligustroglucosid, oleuropein, ligustroglucosid, ligustroglucosidic acid, and ligustroglucosid G13.
[0010] The phenylethanol compounds include one or more of salidroside, tyrosol, hydroxytyrosol, echinacoside and verbascoside.
[0011] The triterpenoid compounds include one or more of oleanolic acid, ursolic acid, acetyloleanolic acid and acetylursolic acid.
[0012] Preferably, in the traditional Chinese medicine composition, the mass ratio of the iridoid compounds, phenylethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide is 1:0.5-1.0:0.3-1.0:54.5-64.3.
[0013] Preferably, in the traditional Chinese medicine composition, the mass ratio of the iridoid compounds, phenylethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide is 1:1.0:0.9:63.8.
[0014] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition in preparing medicine for treating and / or preventing osteoporosis.
[0015] Preferably, the osteoporosis includes primary osteoporosis.
[0016] Preferably, the osteoporosis comprises postmenopausal osteoporosis.
[0017] Preferably, the osteoporosis comprises postmenopausal osteoporosis with concomitant iron overload.
[0018] The present invention also provides a medicine for treating and / or preventing osteoporosis, wherein the medicine uses the above-mentioned traditional Chinese medicine composition as an active ingredient.
[0019] Preferably, the drug further comprises other pharmaceutically acceptable excipients.
[0020] Preferably, the medicine comprises decoction, decoction paste, pills, powder, tablets or capsules.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] (1) The present invention utilizes a variety of solvents to perform reflux extraction on Ligustrum lucidum fruit, thereby improving the extraction rate of effective components.
[0023] (2) The present invention analyzes the quantitative ratios of the components of Ligustrum lucidum and exerts the optimal synergistic effect of the traditional Chinese medicine composition by changing the quantitative ratios of the components of Ligustrum lucidum.
[0024] (3) The mass ratio of the various active components in Ligustrum lucidum, namely, phenylethyl alcohol: cyclopentane ether terpenes: triterpenes: Ligustrum lucidum polysaccharide, is 1:0.5-1.0:0.3-1.0:54.5-64.3, especially the mass ratio of phenylethyl alcohol: cyclopentane ether terpenes: triterpenes: Ligustrum lucidum polysaccharide is 1:1.0:0.9:63.8. At this time, the four components work synergistically to achieve the best effect in treating osteoporosis.
[0025] (4) The effect of the Chinese medicine composition of the present invention on promoting the zebrafish skull staining area and cumulative optical density is better than that of the extract of Ligustrum lucidum slices (raw product, wine steamed product) and positive drugs. After experimental verification, the effect of the Chinese medicine composition of the present invention on promoting the zebrafish skull staining area and cumulative optical density is 1.2 to 1.4 times that of Ligustrum lucidum slices. Therefore, the Chinese medicine composition of the present invention can significantly improve the bone mineralization formation of osteoporosis and repair cartilage damage, especially for osteoporosis with iron overload.
[0026] (5) The pharmaceutical composition of the present invention has good safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is the extraction rate of Ligustrum lucidum slices; in the figure, 95% EA: 95% ethanol extract; 70% EA: 70% ethanol extract; dd Water: water extract; R1-R8: raw product; W1-W2: wine-distilled product.
[0028] Figure 2 HPLC chromatograms; A: HPLC chromatogram of mixed reference (210nm, 230nm, 280nm, 1: Hydroxytyrosol; 2: Salidroside; 3: Tyrosol; 4: Echinacoside; 5: Verbascoside; 6: Ligustrum lucidum; 7: Oleuropein; 8: Oleanolic acid; 9: Ursolic acid). B: HPLC chromatogram of sample solution (210nm, 95% EA: 95% ethanol extract; 70% EA: 70% ethanol extract; dd Water: water extract).
[0029] Figure 3 Representative images of zebrafish skull staining; in the figure, CON: blank group; DMSO: solvent control group; MOD: model group; DFO: positive control group (deferoxamine); SrR: positive control group (strontium ranelate); 1-16: orthogonal experimental group.
[0030] Figure 4 The effect of Ligustrum lucidum composition on zebrafish bone mineralization (n=12, In the figure, A: zebrafish bone mineralization area (BMA); B: zebrafish bone mineralization cumulative optical density (IOD). CON: blank group; DMSO: solvent control group; MOD: model group; DFO: positive control group (deferoxamine); SrR: positive control group (strontium ranelate); 1-16: orthogonal experimental group. ###P<0.001, compared with DMSO group; **P<0.01, ***P<0.001, compared with MOD group.
[0031] Figure 5 The effect of the Ligustrum lucidum composition on zebrafish cartilage formation (n=12, In the figure, IOD: zebrafish cartilage cumulative optical density; CON: blank group; DMSO: solvent control group; MOD: model group; DFO: positive control group (deferoxamine); SrR: positive control group (strontium ranelate); 1-16: orthogonal experimental group. *P<0.05, ***P<0.001, compared with the MOD group.
[0032] Figure 6 Representative images of zebrafish skull staining; in the figure, CON: blank group; DMSO: solvent control group; MOD: model group; 5-1, 5-2, 5-3: orthogonal experimental group 5; 10-1, 10-2, 10-3: orthogonal experimental group 10; 16-1, 16-2, 16-3: orthogonal experimental group 16; A3B2C3-1, A3B2C3-2, A3B2C3-3: optimal combination group.
[0033] Figure 7 Figure 1 shows the effect of Ligustrum lucidum composition on bone mineralization in zebrafish (n=12, In the figure, A: zebrafish bone mineralization area (BMA); B: zebrafish bone mineralization cumulative optical density (IOD). Among them, CON: blank group; DMSO: solvent control group; MOD: model group; 5-1, 5-2, 5-3: orthogonal experimental group 5; 10-1, 10-2, 10-3: orthogonal experimental group 10; 16-1, 16-2, 16-3: orthogonal experimental group 16; A3B2C3-1, A3B2C3-2, A3B2C3-3, best combination group; ###P<0.001, compared with DMSO group; ***P<0.001, compared with MOD group.
[0034] Figure 8 Figure 2 shows the effect of Ligustrum lucidum composition on promoting cartilage formation in zebrafish (n=12, In the figure, IOD: cumulative optical density of zebrafish cartilage; CON: blank group; DMSO: solvent control group; MOD: model group; 5-1, 5-2, 5-3: orthogonal experimental group 5; 10-1, 10-2, 10-3: orthogonal experimental group 10; 16-1, 16-2, 16-3: orthogonal experimental group 16; A3B2C3-1, A3B2C3-2, A3B2C3-3, best combination group; ***P<0.001, compared with the MOD group.
[0035] Fig. 9 Figure 2 shows the effect of Ligustrum lucidum active ingredients used alone or in combination on promoting bone mineralization area (BMA) in zebrafish (n=12, In the figure, A: teruginosa (0.5 / 5 / 25 / 50 / 100μM); B: salidroside (0.5 / 5 / 25 / 50 / 100μM); C: oleanolic acid (0.5 / 5 / 25 / 50 / 100μM); D: Ligustrum lucidum polysaccharide (25 / 50 / 100 / 125 / 250μg / mL); E: a composition of teruginosa, salidroside, oleanolic acid and Ligustrum lucidum polysaccharide in a ratio of 1:1:1:1 (25 / 50 / 100 / 125 / 250μg / mL); CON: blank group; DMSO: solvent control group; MOD: model group; DFO: positive control group (deferoxamine); ###P<0.001, compared with the DMSO group; **P<0.01, ***P<0.001, compared with the MOD group.
[0036] Fig.10 It is a dose-effect curve diagram of the effective ingredients of Ligustrum lucidum and the composition; in the figure, Fa: the increase in staining area in the treatment group compared with the model group.
[0037] Fig.11 It is the CI-effect curve diagram of the Ligustrum lucidum composition; in the figure, Fa: the increase in staining area of the treatment group compared with the model group; CI: combined drug index.
[0038] Fig.12 Representative images of zebrafish skull staining; in the figure, CON: blank group; DMSO: solvent control group; MOD: model group; DFO: positive control group (deferoxamine); SrR: positive control group (strontium ranelate); A3B2C3: Chinese medicine combination group; FLL: Ligustrum lucidum slices (raw group); WFLL: Ligustrum lucidum slices (steamed with wine group); 95% EA: 95% ethanol extract group; 70% EA: 70% ethanol extract group; dd Water: water extract group.
[0039] Fig.13 Figure 1 shows the bone mineralization of zebrafish enhanced by the Ligustrum lucidum composition (n=12, In the figure, A: zebrafish bone mineralization area (BMA); B: zebrafish bone mineralization cumulative optical density (IOD). CON: blank group; DMSO: solvent control group; MOD: model group; DFO: positive control group (deferoxamine); SrR: positive control group (strontium ranelate); A3B2C3: Chinese medicine combination group; FLL: Ligustrum lucidum slices (raw product group); WFLL: Ligustrum lucidum slices (steamed product group); 95% EA: 95% ethanol extract group; 70% EA: 70% ethanol extract group; dd Water: water extract group; ###P<0.001, compared with DMSO group; ***P<0.001, compared with A3B2C3 group. DETAILED DESCRIPTION
[0040] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but the protection scope of the present invention is not limited thereto, and the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. The experimental methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials, unless otherwise specified, can be obtained from commercial channels.
[0041] In the following embodiments, the cyclopentane compounds include one or more of ligustrin, oleuropein, ligustrin, ligustric acid, and ligustrin G13; the phenylethanol compounds include one or more of salidroside, tyrosol, hydroxytyrosol, echinacea glycoside, and verbascoside; the triterpenoid compounds include one or more of oleanolic acid, ursolic acid, acetyloleanolic acid, and acetylursolic acid.
[0042] Example 1: Preparation of Ligustrum lucidum extract
[0043] S1. Pretreatment: The Ligustrum lucidum medicinal materials were harvested within one month before and after the winter solstice (origin: Jiangsu), and a total of 8 batches of Ligustrum lucidum medicinal materials R1-R8 at different time stages were harvested (specific harvesting time: R1: 2021.12.05; R2: 2021.12.10; R3: 2021.12.16; R4: 2021.12.21; R5: 2021.12.27; R6: 2024.01.02; R7: 2024.01.07; R8: 2024.01.07). Remove impurities, wash, and dry for later use. Take two batches of Ligustrum lucidum medicinal materials (R4, R6), add yellow wine and mix well, the material-liquid ratio is 5:1 (the ratio of Ligustrum lucidum medicinal materials to yellow wine is 5:1), soak and mix for 2 hours, place in a suitable steaming container and steam for 12 hours, take out Ligustrum lucidum, and dry to obtain wine Ligustrum lucidum W1 and W2, of which W1 is the R4 wine steamed product, and W2 is the R6 wine steamed product. Take appropriate amounts of Ligustrum lucidum and wine Ligustrum lucidum of each batch, crush them, sieve (60 mesh) and set aside.
[0044] S2. Extraction: Accurately weigh 30g of Ligustrum lucidum decoction slice powder, add 95% ethanol solution, the solid-liquid ratio is 1:10 (g / mL), reflux extraction 3 times, each time for 1h, and combine the 3 extracts as 95% ethanol extract. Add 70% ethanol solution to the extracted Ligustrum lucidum drug residues, the solid-liquid ratio is 1:10 (g / mL), reflux extraction 3 times, each time for 1h, and combine the 3 extracts as 70% ethanol extract. Add distilled water to the extracted Ligustrum lucidum drug residues again, the solid-liquid ratio is 1:10 (g / mL), reflux extraction 3 times, each time for 1h, and combine the 3 extracts as water extracts.
[0045] S3. Concentration: The combined 95% ethanol extract, 70% ethanol extract and water extract are concentrated under reduced pressure by a rotary evaporator to an extract-like state.
[0046] S4. Freeze-drying: The concentrated extracts were transferred to sample plates, pre-frozen at -80°C overnight and then freeze-dried. The freeze-dried samples were taken out, weighed and the extraction rate was calculated. The samples were sealed and stored in a cool and dry place at room temperature for later use.
[0047]
[0048] Figure 1 It is the extraction yield of Ligustrum lucidum slices. As can be seen from the figure, compared with the traditional extraction method, the present invention adopts 95% ethanol solution, 70% ethanol solution and distilled water for gradient reflux extraction, which can significantly improve the extraction yield, wherein the 95% ethanol extract accounts for 43.52±2.85%, the 70% ethanol extract accounts for 10.28±1.09%, and the distilled water extract accounts for 6.19±0.81%. Therefore, the extraction method used in the present invention can fully dissolve the effective ingredients of traditional Chinese medicine and improve the utilization rate of traditional Chinese medicine.
[0049] Example 2: Analysis of the quantitative ratios among the components of Ligustrum lucidum
[0050] In this example, the freeze-dried powders of 95% ethanol extract, 70% ethanol extract and water extract of Ligustrum lucidum slices were analyzed by HPLC and anthrone-sulfuric acid colorimetry to determine the quantitative ratios of the components of Ligustrum lucidum samples obtained under different conditions.
[0051] S1. Preparation of sample solution:
[0052] Weigh the freeze-dried powder of 95% ethanol extract, 70% ethanol extract and water extract of Ligustrum lucidum slices accurately, make up to volume with methanol, and add methanol after ultrasonication for 30 minutes to make a 0.5 mg / mL solution. Take appropriate amount of each solution and filter through 0.22 μm microporous membrane to obtain sample solution, and store in a refrigerator at 4°C for later use.
[0053] S2. Preparation of reference solution:
[0054] The reference substances of terglucosidoside, salidroside, oleuropein, hydroxytyrosol, tyrosol, echinacoside, verbascoside, oleanolic acid and ursolic acid were accurately weighed and dissolved in methanol to prepare reference substance solutions with concentrations of 560, 460, 480, 720, 630, 550, 470, 630 and 560 μg / mL, respectively. Then 1 mL of each reference substance was taken in a 10 mL volumetric flask and fixed to volume with methanol to obtain a mixed standard solution of terglucosidoside (56 μg / mL), salidroside (46 μg / mL), oleuropein (48 μg / mL), hydroxytyrosol (72 μg / mL), tyrosol (63 μg / mL), echinacoside (55 μg / mL), verbascoside (47 μg / mL), oleanolic acid (63 μg / mL) and ursolic acid (56 μg / mL), which was stored in a refrigerator at 4°C for later use.
[0055] S3. HPLC determination conditions and methods of iridoids, phenylethanol and triterpenes:
[0056] The HPLC was Agilent 1200 and the chromatographic column was ZORBAX SB-C 18 Chromatographic column (250mm×4.6mm, 5μm); mobile phase A: acetonitrile, B: 0.1% phosphoric acid solution; gradient elution; column temperature 25°C; detection wavelengths selected 210nm, 230nm, 280nm; flow rate 1mL / min; injection volume 20μL. The specific elution method is shown in Table 1, and the test results are shown in Figure 2 As shown in Tables 2 to 5.
[0057] Table 1. HPLC mobile phase gradient elution method
[0058] Time / min A / % B / % 0-10 7-12 93-88 10-35 12-25 88-75 35-52 25-41 75-59 52-62 41-95 59-5 62-77 95 5 77-82 95-7 5-93
[0059] S4. Determination of polysaccharides from Ligustrum lucidum by anthrone-sulfuric acid colorimetry:
[0060] In this step, the content of glossy privet polysaccharide in S1 freeze-dried powder is determined by anthrone-sulfuric acid colorimetry, wherein the preparation method of anthrone reagent is as follows: accurately weigh 0.2g of anthrone in a 100mL brown volumetric flask, add 80% concentrated sulfuric acid to dissolve and dilute to volume, mix well, and obtain 2mg / mL of anthrone reagent. The determination method of glossy privet polysaccharide is as follows:
[0061] (1) Preparation of glucose standard solution and investigation of linear relationship: Accurately weigh 5 mg of anhydrous glucose into a 50 mL volumetric flask, add water to dissolve and dilute to volume, shake well, and obtain a polysaccharide reference stock solution of 0.1 mg / mL. Accurately pipette 0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 mL of the reference stock solution into a 10 mL stoppered glass tube, dilute to 2 mL with distilled water, and shake well. Immediately add 4 mL of anthrone reagent to each test tube, mix well, heat in a boiling water bath for 15 min, and quickly immerse in an ice water bath to cool for 15 min. Measure the absorbance of each tube at a wavelength of 625 nm with the solvent tube as the blank. Draw the glucose standard curve AC with the reference concentration C as the horizontal axis and the absorbance value A as the vertical axis.
[0062] (2) Preparation and determination of sample solution:
[0063] Weigh 4 mg of freeze-dried powder of 95% ethanol extract, 70% ethanol extract and water extract of Ligustrum lucidum slices respectively, dissolve in distilled water, and prepare 0.08 mg / mL test solution. Pipette 2 mL of each test solution into a 10 mL stoppered glass tube, immediately add 4 mL of anthrone reagent to each test tube, mix well, heat in a boiling water bath for 15 minutes, quickly cool in an ice water bath for 15 minutes, and then measure the absorbance of each sample solution at a wavelength of 625 nm to calculate the polysaccharide content. The test results are as follows: Figure 2 As shown in Tables 2 to 5.
[0064] Figure 2 The HPLC chromatograms of the mixed standard of Ligustrum lucidum and the 95% ethanol extract, 70% ethanol extract and water extract. It can be seen from the figure that the precision, stability and repeatability of the HPLC and UV analysis methods are good.
[0065] Table 2. Linear relationship study of various components in Ligustrum lucidum (n=6)
[0066] Standard curve <![CDATA[R 2 ]]> Hydroxytyrosol y=237.3x-70.271 <![CDATA[R 2 =0.9999]]> Salidroside y=53.265x-29.4 <![CDATA[R 2 =0.9996]]> Tyrosol y=158.1x-22.627 <![CDATA[R 2 =0.9993]]> Echinacoside y=38.8x-9.335 <![CDATA[R 2 =0.9991]]> Verbascoside y=14.444x+0.0225 <![CDATA[R 2 =0.9991]]> Ligustrum lucidum y=16.336x-22.078 <![CDATA[R 2 =0.9994]]> Oleuropein y=57.999x+4.6234 <![CDATA[R 2 =0.9997]]> Oleanolic acid, ursolic acid y=9.5556x-8.5393 <![CDATA[R 2 =0.9995]]> Ligustrum lucidum polysaccharide y=0.0291x-0.1713 <![CDATA[R 2 =0.9993]]>
[0067] As can be seen from Table 2, the linearity of ligusticum glycoside, salidroside, oleuropein, hydroxytyrosol, tyrosol, echinacoside, verbascoside, oleanolic acid, ursolic acid and polysaccharide of Ligustrum lucidum was good, with recoveries between 95% and 105% and RSD% < 4%.
[0068] Table 3. Contents of 9 components and polysaccharides in Ligustrum lucidum (percentage of crude drug content, n=3,
[0069]
[0070] Note: The percentage content refers to the percentage content of each component in the crude drug; R1-R8: raw Ligustrum lucidum harvested within one month before and after the winter solstice; W1: R4 steamed with wine for 12 hours; W2: R6 steamed with wine for 12 hours
[0071] Table 4. Quantity ratio of components of Ligustrum lucidum slices (n=3)
[0072]
[0073]
[0074] Note: The percentage content refers to the percentage content of the component in the crude drug; R1-R8: raw Ligustrum lucidum harvested within one month before and after the winter solstice; W1: R4 steamed with wine for 12 hours; W2: R6 steamed with wine for 12 hours. ***P<0.001, compared with R4; ###P<0.001, compared with R6.
[0075] Combining Tables 3 and 4, it can be seen that the contents of phenylethanol compounds, cyclopentane compounds, triterpenoids, and polysaccharides in Ligustrum lucidum (R1-R8) harvested at different times before and after the winter solstice are quite different, and the quantitative ratios of the components of Ligustrum lucidum are quite different. In addition, for the wine-steamed products of Ligustrum lucidum steamed for 12 hours (W1-W2), the quantitative ratios of phenylethanol compounds, cyclopentane compounds, triterpenoids, and polysaccharides in Ligustrum lucidum are significantly different from those in the raw products, among which the proportion of phenylethanol compounds is significantly increased, and the proportion of cyclopentane compounds is significantly decreased (P<0.05). Wine steaming changes the quantitative ratios of the components of Ligustrum lucidum.
[0076] Table 5. Mass concentration of each component of Ligustrum lucidum slices in different solvents (n = 3)
[0077]
[0078] Note: Mass concentration refers to the mass ratio of the component to the freeze-dried powder of the extract; R1-R8: raw Ligustrum lucidum harvested within one month before and after the winter solstice; W1: R4 steamed with wine for 12 hours; W2: R6 steamed with wine for 12 hours; 95%: 95% ethanol extract; 70%: 70% ethanol extract; Water: water extract.
[0079] As can be seen from Table 5, the contents of the effective ingredients of Ligustrum lucidum in different extraction solvents vary greatly, among which iridoids and triterpenes are mainly present in the 95% ethanol extraction part, and phenylethanol and Ligustrum lucidum polysaccharide are mainly present in the 70% ethanol extraction part and the water extraction part. In this embodiment, the extracts extracted by different solvents are recombined, and the amount ratio of phenylethanol, iridoids, triterpenes, and Ligustrum lucidum polysaccharide components is further changed, so that the combined drug can play the best anti-osteoporosis effect.
[0080] Example 3: Optimization of the quantitative ratio between the components of Ligustrum lucidum
[0081] In this example, 2 dpf (days post fertilization) zebrafish embryos (purchased from Nanjing Yishulihua Co., Ltd.) and ammonium ferric citrate-induced zebrafish osteoporosis model were used as the efficacy model for optimizing the quantitative ratio between Ligustrum lucidum components. The specific steps are as follows:
[0082] S1. Zebrafish culture:
[0083] S11. Grouping:
[0084] After 24 hours of adaptive culture, 2 dpf zebrafish embryos were divided into blank control group (CON), solvent control group (DMSO), model group (MOD), positive control group and different treatment groups, with 20 embryos in each group and 10 embryos in each well.
[0085] S12. Establishment of iron overload osteoporosis model:
[0086] At 3 dpf to 6 dpf, embryos in the CON and DMSO groups were cultured with E3 solution (2.925 g / L, CaCl2 0.366 g / L, KCl0.127 g / L, MgSO4 0.429 g / L), and embryos in all other groups were treated with ferric ammonium citrate (FAC, 0.1 mg / mL) solution to induce an iron overload osteoporosis model.
[0087] Zebrafish were cultured in a constant temperature incubator (28±0.5℃, 14h / 10h light-dark cycle), and the solution was changed regularly every day. Each group was treated from 7dpf, among which the CON group was given E3 solution; the DMSO group and the model group were given 0.2% DMSO / E3 solution; and the other groups were treated with the corresponding solution. The solution was changed regularly every day for 4 consecutive days, and the number of zebrafish deaths was recorded until 10dpf.
[0088] It was found through records that the mortality rate of all treatment groups was <30% four days after zebrafish administration, indicating that the Ligustrum lucidum composition has good safety for zebrafish at concentrations of 100 μg / mL and below.
[0089] S2. Zebrafish staining:
[0090] After the drug solution was drained from each group of surviving zebrafish in step S1, MS-222 solution (100 mg / L) was added to anesthetize and kill, and then MS-222 was drained and 4% paraformaldehyde tissue fixative was added to fix for 2 hours. 50% ethanol solution was added to dehydrate for 10 minutes. After dehydration, the ethanol solution was drained, Alizarin red-Alcian blue acid-free double stain was added, and staining was carried out overnight on a shaker at room temperature. The dye solution was drained, washed twice with PBS, and bleaching solution (1% KOH / 1.5% H2 O 2 ) and bleached for 1 hour. The bleach solution was aspirated, and the fish were washed twice with PBS, dried, and stored in 50% glycerol / 0.1% KOH solution for further analysis.
[0091] The preparation steps of Alizarin Red-Alcian Blue acid-free double stain are as follows:
[0092] Liquid A: Alcian blue dye solution
[0093] Accurately weigh Alcian blue powder and dissolve it in 70% ethanol solution to prepare 0.4% Alcian blue dye solution. Take 12.5mL of 0.4% Alcian blue dye solution in a 250mL volumetric flask, add 175mL of 95% ethanol, 12.5mL of 1M MgCl 2 The solution was then washed with dd H 2 O to make up to volume to obtain solution A, which was stored at room temperature for later use.
[0094] Solution B: 0.5% Alizarin Red dye solution. Dissolve 0.05 g of Alizarin Red powder in 10 mL of ddHO. 2 O and store at room temperature for later use.
[0095] Alizarin Red-Alcian Blue Acid-Free Double Stain: Before use, mix 100 mL of Solution A and 1 mL of Solution B (prepare and use immediately).
[0096] S3. Zebrafish skull analysis:
[0097] The zebrafish stained in step S2 were placed on a slide, observed under an optical microscope, and photographed using a microscopic imaging system. The bone mineral area (BMA) and integrated optical density (IOD) of zebrafish and the integrated optical density (IOD) of cartilage were obtained using Image J analysis. GraphPad Prism 8.0 was used for data analysis, and the Tukey test was used to determine the differences between the groups. The experimental data were expressed as mean ± standard deviation. P < 0.05 indicates that the difference is statistically significant.
[0098] Combination Figure 3 and Figure 4 It can be seen that compared with the blank group, the BMA and IOD of the model group were significantly decreased (P<0.05), indicating that the model was successfully established. Positive drugs DFO and SrR can significantly promote bone mineralization in zebrafish (P<0.05). The treatment group (1-16) not only reversed the osteoporosis induced by iron overload, but also further promoted the mineralization of zebrafish bones (P<0.05).
[0099] In addition, analysis of cartilage formation by Alcian blue staining showed that the positive drugs DFO and SrR could significantly promote cartilage formation in zebrafish and repair cartilage damage caused by osteoporosis (P<0.05); the Ligustrum lucidum treatment groups 5, 10, and 16 could also significantly repair cartilage damage caused by osteoporosis in zebrafish (P<0.05) ( Figure 5 ).
[0100] S4. Optimization of the quantitative ratio between Ligustrum lucidum fruit components:
[0101] In this step, the ratio of 95% ethanol extract and 70% ethanol extract was changed to change the ratio of components of Ligustrum lucidum. Three factors, 95% ethanol extract (A), 70% ethanol extract (B) and dosage (C), were selected to establish a factor level table, and four levels were selected for each factor (Table 6). After 24 hours of adaptive culture, 2dpf zebrafish embryos were divided into a blank control group (CON), a solvent control group (DMSO), a model group (MOD), a positive drug deferoxamine group (DFO, 100μM), a positive drug strontium ranelate group (SrR, 100μM) and a treatment group (1-16 groups), with 20 pieces in each group and 10 pieces in each well.
[0102] The zebrafish skull BMA and IOD were used as evaluation indicators, and the entropy method was used to comprehensively evaluate multiple indicators to optimize the ratio of components of Ligustrum lucidum (Table 7). Then the treatment group that can significantly promote zebrafish bone formation and the best combination group were selected for further verification, and each group was verified 3 times in parallel to screen out the best ratio of components of Ligustrum lucidum for the treatment of osteoporosis.
[0103] Table 6. Orthogonal test factor level table
[0104]
[0105] Table 7. Summary of weight calculation results using entropy method
[0106] item Information entropy value e Information utility value d Weight coefficient w BMA 0.9978 0.0022 39.57% IOD 0.9966 0.0034 60.43%
[0107] The results of the orthogonal experiment are shown in Table 8. Taking the BMA and IOD comprehensive scores of zebrafish skull mineralization as evaluation indicators, the range analysis found that the three factors were ranked as C>A>B, and the best combination was A3B2C3, that is, 95% ethanol extract and 70% ethanol extract were mixed in a mass ratio of 1:12 and administered at a dose of 50 μg / mL. At this time, the ratio of the components in Ligustrum lucidum was phenylethanol: cyclopentane ether terpenes: triterpenes: Ligustrum lucidum polysaccharide = 1:1.0:0.9:63.8.
[0108] Table 8. Orthogonal design and result analysis (n=12)
[0109]
[0110] Note: BMA: zebrafish skull mineralization area; IOD: zebrafish skull mineralization cumulative optical density.
[0111] The results of the orthogonal test showed that treatment groups 5, 10, and 16 could significantly promote bone formation in zebrafish. Therefore, treatment groups 5, 10, and 16 were further verified with the best combination A3B2C3 group, and each group was verified three times in parallel to screen out the optimal ratio of components of Ligustrum lucidum for anti-osteoporosis. Figure 6 The results of bone mineralization analysis are shown in Figure 7 As shown. Compared with the blank group, the BMA and IOD of the model group decreased significantly (P<0.05), indicating that the model was successfully established. Ligustrum lucidum treatment group 5, 10, 16 and A3B2C3 promoted the mineralization of zebrafish bones (P<0.05). In addition, Ligustrum lucidum treatment group 5, 10, 16 and A3B2C3 could significantly repair the cartilage damage caused by osteoporosis in zebrafish ( Figure 8 , P<0.05), and there was no significant difference among the three parallel experiments.
[0112] The zebrafish bone mineralization BMA and IOD were comprehensively scored, and the results are shown in Table 9. As can be seen from Table 9, compared with treatment groups 5 and 16, the best combination group A3B2C3 can significantly promote zebrafish bone mineralization (P<0.05), and compared with treatment group 10, the best combination group A3B2C3 has a better therapeutic trend on zebrafish bone mineralization. It shows that the multi-components in Ligustrum lucidum can significantly treat iron overload-induced osteoporosis when the mass ratio of phenylethanol: cyclopentane ether terpenes: triterpenes: Ligustrum lucidum polysaccharide is 1:1.0:0.9:63.8, and the dosage is 50μg / mL.
[0113] Table 9. Orthogonal test verification results (n=3)
[0114]
[0115] Note: BMA: mineralized area of zebrafish skull; IOD: cumulative optical density of zebrafish skull mineralization. **P<0.01, ***P<0.001, compared with A3B2C3 group.
[0116] In summary, when the mass ratio of multiple active components in Ligustrum lucidum is 1:0.5-1.0:0.3-1.0:54.5-64.3, it has a good anti-osteoporosis effect; when the mass ratio of multiple components in Ligustrum lucidum is 1:1.0:0.9:63.8, the anti-osteoporosis effect is optimal.
[0117] Example 4: Study on the synergistic effect between components of Ligustrum lucidum
[0118] The zebrafish osteoporosis model was constructed using the method described in Example 3 to investigate the interaction between iridoids, phenethyl alcohols, triterpenes and Ligustrum lucidum polysaccharides in Ligustrum lucidum. The pharmacodynamic interaction forms include additive (1+1=2), synergistic (1+1>2) or antagonistic (1+1<1) effects.
[0119] The representative components of each component, teruginosa, salidroside, oleanolic acid and polysaccharide of Ligustrum lucidum were selected as the research objects. After 24 hours of adaptive culture, 2dpf zebrafish embryos were divided into blank control group (CON), solvent control group (DMSO), model group (MOD), positive drug deferoxamine group (DFO, 100μM), teruginosa group (0.5 / 5 / 25 / 50 / 100μM), salidroside group (0. 5 / 5 / 25 / 50 / 100μM), oleanolic acid group (0.5 / 5 / 25 / 50 / 100μM), Ligustrum lucidum polysaccharide group (25 / 50 / 100 / 125 / 250μg / mL) and the combination group of teruginosa, salidroside, oleanolic acid and Ligustrum lucidum polysaccharide in a ratio of 1:1:1:1 (25 / 50 / 100 / 125 / 250μg / mL), 20 pieces in each group and 10 pieces in each well. The alizarin red staining area of zebrafish skull was analyzed, and the increase in BMA in the treatment group compared with the model group was used as the effect value (Fa). Based on the "Chou-Talalay" model, the combination index (CI) was calculated using Calcusyn software. The CI value was used to evaluate the synergistic (CI<1), additive (CI=1) and antagonistic (CI>1) effects of drug compatibility, thereby determining the interaction of the combination.
[0120]
[0121] like Fig. 9 As shown in the figure, compared with the DMSO group, the BMA in the MOD group decreased significantly (P<0.05), indicating that the model was successfully established. Compared with the MOD group, the positive drug DFO, different concentrations of teruginosa glycosides, salidroside, oleanolic acid, and polysaccharides of Ligustrum lucidum alone and the combined use of the four components significantly promoted bone mineralization in zebrafish (P<0.05). From the dose-effect curve ( Fig.10 ) It can be seen that compared with the treatment groups of Ligustrum lucidum, salidroside, oleanolic acid, and Ligustrum lucidum polysaccharide alone, the combination has a stronger effect in promoting zebrafish bone mineralization. Calculate the CI value of the combination, such as Fig.11 It can be seen that when the total concentration of the composition is ≥50 μg / mL, CI<1, indicating that the components in the composition work synergistically to promote bone mineralization.
[0122] Combination Fig. 9 and Fig.10It can be seen that phenylethanol, iridoids, triterpenes and Ligustrum lucidum polysaccharides in Ligustrum lucidum have a synergistic effect. When the mass ratio of the multiple components in Ligustrum lucidum is phenylethanol: iridoids: triterpenes: Ligustrum lucidum polysaccharides is 1:1.0:0.9:63.8, the components synergize and exert the best anti-osteoporosis effect.
[0123] Comparative Example 1:
[0124] The zebrafish osteoporosis model was constructed by the method described in Example 3, and was used to investigate the anti-osteoporosis abilities of the Chinese medicine composition obtained in Example 4, Ligustrum lucidum slices (raw product, wine steamed product), positive drugs deferoxamine (DFO) and strontium ranelate (SrR). The investigation results are as follows: Fig.12 and 13 Among them, the Chinese medicine combination is the best combination group.
[0125] Combination Fig.12 and Fig.13 It can be seen that compared with the DMSO group, the BMA and IOD of the MOD group were significantly decreased (P<0.05), indicating that the model was successfully established. Compared with the MOD group, the positive drugs DFO and SrR, the treatment groups A3B2C3, FLL, WFLL, 95% EA, 70% EA and dd Water groups all significantly promoted the bone mineralization of zebrafish (P<0.05). In addition, the ability of the Chinese medicine combination group A3B2C3 to promote bone formation was much higher than that of the Ligustrum lucidum slices and the positive drugs ( Fig.13 , P<0.05), indicating that optimizing the quantitative ratio of Ligustrum lucidum components can exert a stronger anti-osteoporosis effect.
[0126] Therefore, compared with the extract of Ligustrum lucidum slices and positive drugs, the Chinese medicine composition of the present invention has stronger anti-osteoporosis activity.
[0127] The embodiments are preferred implementations of the present invention, but the present invention is not limited to the above-mentioned implementations. Any obvious improvements, substitutions or modifications that can be made by those skilled in the art without departing from the essential content of the present invention belong to the protection scope of the present invention.
Claims
1. A Chinese medicine composition for treating and / or preventing osteoporosis, characterized in that: The traditional Chinese medicine composition comprises iridoid compounds, phenethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide.
2. The Chinese medicine composition for treating and / or preventing osteoporosis according to claim 1, characterized in that: The iridoid compounds, phenethyl alcohol compounds, triterpenoid compounds and Ligustrum lucidum polysaccharide are extracted from Ligustrum lucidum fruits.
3. The Chinese medicine composition for treating and / or preventing osteoporosis according to claim 1, characterized in that: The iridoid ether terpenoid compound includes one or more of privet glycoside, oleuropein, privet glycoside, privet acid, and privet glycoside G13; The phenylethanol compound includes one or more of salidroside, tyrosol, hydroxytyrosol, echinacoside, and verbascoside; The triterpenoid compounds include one or more of oleanolic acid, ursolic acid, acetyloleanolic acid and acetylursolic acid.
4. The Chinese medicine composition for treating and / or preventing osteoporosis according to claim 1, characterized in that: In the traditional Chinese medicine composition, the mass ratio of the iridoid compounds, the phenylethyl alcohol compounds, the triterpenoid compounds and the Ligustrum lucidum polysaccharide is 1:0.5-1.0:0.3-1.0:54.5-64.
3.
5. The Chinese medicine composition for treating and / or preventing osteoporosis according to claim 4, characterized in that: In the traditional Chinese medicine composition, the mass ratio of the iridoid compounds, the phenylethyl alcohol compounds, the triterpenoid compounds and the Ligustrum lucidum polysaccharide is 1:1.0:0.9:63.
8.
6. Use of the Chinese medicine composition according to claim 1 in the preparation of a medicament for treating and / or preventing osteoporosis.
7. The use according to claim 6, characterized in that: The osteoporosis includes primary osteoporosis.
8. The use according to claim 7, characterized in that: The osteoporosis includes postmenopausal osteoporosis.
9. A drug for treating and / or preventing osteoporosis, characterized in that: The medicine uses the Chinese medicine composition of claim 1 as an active ingredient.
10. The drug according to claim 9, characterized in that The medicine also contains other pharmaceutically acceptable excipients.
Citation Information
Patent Citations
New medical purpose of privet and pharmaceutical formulation thereof
CN101239083A
Application of iridoid in preparation of anti-osteoporosis medicines
CN102389440A
Preparation method and application of total iridoid glycoside of ligustrum lucidum ait
CN108159122A
